Endothelial monocyte activating polypeptide II: a mediator which activates host response
AssigneeThe Trustees of Columbia University
InventorsDavid M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti
Life of this patent
Estimating the term…
Abstract
This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
Claims78
A purified endothelial monocyte activating polypeptide II.
An effector cell activating protein comprising a polypeptide having an amino acid sequence wherein at least four amino acid residues are the same as RIGRIVT and are in the same relative positions.
Dependencies are inferred from the claim text.